985-12-6

Basic information

• Product Name: Drotaverine hydrochloride
• Synonyms: 1,2,3,4-Tetrahydro-6,7-diethoxy-1-((3,4-diethoxyphenyl) methylene)-isoquinoline hydrochloride;1-(3,4-diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydro-isoquinolin;drotaveriniumchloride;isoquinoline,1,2,3,4-tetrahydro-6,7-diethoxy-1-((3,4-diethoxyphenyl)methylene);no-spa;no-spahydrochloride;tetraspasmin-lefa;DROTAVERINE HYDROCHLORIDE
• CAS NO: 985-12-6
• Molecular Formula: C24H32ClNO4
• Molecular Weight: 433.97
• EINECS: 1308068-626-2
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Heterocycles
• Mol File: 985-12-6.mol
• Article Data: 1

Chemical Properties

• Melting Point: 208-212°C
• Boiling Point: 564oC at 760 mmHg
• Flash Point: 240.7oC
• Appearance: pale-yellow crystalline solid
• Density: 1.097 g/cm³
• Vapor Pressure: 5E-14mmHg at 25°C
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Drotaverine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Drotaverine hydrochloride(985-12-6)
• EPA Substance Registry System: Drotaverine hydrochloride(985-12-6)

Safety Data

• Hazardous Substances Data: 985-12-6(Hazardous Substances Data)

Usage

Description

Drotaverine hydrochloride is a synthetic compound that serves as an analogue of papaverine, a naturally occurring opium alkaloid. It exhibits antispasmodic properties, making it a valuable pharmaceutical agent for the treatment of various conditions characterized by involuntary muscle spasms.

Uses

Used in Pharmaceutical Industry:
Drotaverine hydrochloride is used as an antispasmodic agent for the treatment of smooth muscle spasms in conditions such as gastrointestinal disorders, biliary colic, and urinary tract spasms. Its antispasmodic action helps to alleviate pain and discomfort associated with these conditions by relaxing the affected muscles and promoting normal functioning.
As a papaverine analog, Drotaverine hydrochloride shares similar therapeutic benefits with papaverine, but it may offer improved safety and efficacy profiles. This makes it a preferred choice for the management of spasmodic conditions in various patient populations.

InChI:InChI=1/C24H31NO4.ClH/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20;/h9-10,13-16,25H,5-8,11-12H2,1-4H3;1H/b20-13+;

Upstream product

• 38464-04-9 3,4-diethoxy-phenyl-acetic acid 
• 69373-87-1 ethyl 2-(3,4-diethoxyphenyl)acetate 
• 53017-34-8 ethyl 2-(3,4-diethoxyphenyl)-2-oxoacetate 
• 6298-46-0 N-(3,4-diethoxyphenylacetyl)-β-(3,4-diethoxyphenyl)ethylamine 
• 2050-46-6 1,2-diethoxybenzene 
• 526190-09-0 2-(3,4-diethoxyphenyl)acetamide 
• 1137-71-9 1-(3,4-diethoxyphenyl)ethanone 

Relevant articles and documents

Novel method for preparing drotaverine hydrochloride intermediate

The invention discloses a novel method for preparing a drotaverine hydrochloride intermediate, belonging to the technical field of medicine synthesis. The preparation method comprises the following steps: preparing an intermediate 3,4-diethoxyphenylacetic acid with 1,2-diethoxybenzene as a raw material, and preparing the intermediate 3,4-diethoxyphenylacetamide with 3,4-diethoxyphenylacetic acid as a raw material. According to the novel process for preparing the drotaverine hydrochloride intermediate, a method for directly preparing 3,4-diethoxyphenylacetic acid and 3,4-diethoxyphenylethylamine is adopted, and a process for preparing 3,4-diethoxyphenylacetonitrile is avoided, so a reaction step of using sodium cyanide is avoided.